Loading company…
San Francisco biotechnology company developing bromodomain and extra-terminal inhibitors for cancers, led by ZEN-3694.
Founded by Norman W. Wong, Zenith Epigenetics is based in San Francisco, US, and develops bromodomain and extra-terminal inhibitors (BETi) for cancers and other disorders. Its core candidate, ZEN-3694, is in Phase 2 trials for prostate and breast cancer in collaboration with Pfizer. The company raised CAD 4.6 million through PIPE financing from NGN Capital in July 2014. Its stage is listed as Public.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in